• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

哌甲酯对患有注意力缺陷障碍(ADD)的女孩和男孩的比较效果。

Comparative effects of methylphenidate on ADD girls and ADD boys.

作者信息

Pelham W E, Walker J L, Sturges J, Hoza J

出版信息

J Am Acad Child Adolesc Psychiatry. 1989 Sep;28(5):773-6. doi: 10.1097/00004583-198909000-00021.

DOI:10.1097/00004583-198909000-00021
PMID:2676966
Abstract

The effects of 0.3 mg/kg methylphenidate were compared for 12 ADD boys and 12 ADD girls participating in a summer treatment program for children with behavior and/or learning problems. Previous investigations have suggested that ADD girls may differ from ADD boys in some important respects. No information exists regarding whether the effects of the most common treatment for these children, methylphenidate, has comparable effects on boys and girls. The boys and girls were matched for age and IQ. The results revealed equivalent and beneficial effects of methylphenidate for both boys and girls. Methylphenidate therefore would appear to be as useful a treatment for ADD girls as for ADD boys.

摘要

对12名患注意力缺陷多动障碍(ADD)的男孩和12名患ADD的女孩进行了比较,这些孩子都参加了一个针对有行为和/或学习问题儿童的暑期治疗项目,所用药为0.3毫克/千克的哌甲酯。先前的研究表明,患ADD的女孩在某些重要方面可能与患ADD的男孩有所不同。目前尚无信息表明,这些孩子最常用的治疗药物哌甲酯对男孩和女孩的疗效是否相当。男孩和女孩在年龄和智商方面进行了匹配。结果显示,哌甲酯对男孩和女孩都有同等且有益的效果。因此,哌甲酯似乎对患ADD的女孩和患ADD的男孩一样有用。

相似文献

1
Comparative effects of methylphenidate on ADD girls and ADD boys.哌甲酯对患有注意力缺陷障碍(ADD)的女孩和男孩的比较效果。
J Am Acad Child Adolesc Psychiatry. 1989 Sep;28(5):773-6. doi: 10.1097/00004583-198909000-00021.
2
Ginkgo biloba for attention-deficit/hyperactivity disorder in children and adolescents: a double blind, randomized controlled trial.银杏叶提取物治疗儿童和青少年注意缺陷多动障碍:一项双盲、随机对照试验。
Prog Neuropsychopharmacol Biol Psychiatry. 2010 Feb 1;34(1):76-80. doi: 10.1016/j.pnpbp.2009.09.026. Epub 2009 Oct 5.
3
Relative efficacy of long-acting stimulants on children with attention deficit-hyperactivity disorder: a comparison of standard methylphenidate, sustained-release methylphenidate, sustained-release dextroamphetamine, and pemoline.长效兴奋剂对注意力缺陷多动障碍儿童的相对疗效:标准哌醋甲酯、缓释哌醋甲酯、缓释右旋苯丙胺和匹莫林的比较
Pediatrics. 1990 Aug;86(2):226-37.
4
Attention deficit disorder with and without hyperactivity: clinical response to three dose levels of methylphenidate.伴或不伴多动的注意力缺陷障碍:对三种剂量水平哌甲酯的临床反应
Pediatrics. 1991 Apr;87(4):519-31.
5
Modafinil as a treatment for Attention-Deficit/Hyperactivity Disorder in children and adolescents: a double blind, randomized clinical trial.莫达非尼治疗儿童和青少年注意力缺陷/多动障碍:一项双盲随机临床试验。
Prog Neuropsychopharmacol Biol Psychiatry. 2008 Jan 1;32(1):145-9. doi: 10.1016/j.pnpbp.2007.07.025. Epub 2007 Aug 8.
6
ADHD in girls: clinical comparability of a research sample.女童注意力缺陷多动障碍:一个研究样本的临床可比性
J Am Acad Child Adolesc Psychiatry. 1999 Jan;38(1):40-7. doi: 10.1097/00004583-199901000-00018.
7
Attention deficit disorder and the effect of methylphenidate on attention, behavioral, and cardiovascular functioning.
J Clin Psychiatry. 1984 Nov;45(11):473-6.
8
[Attention in hyperkinetic children: a signal detection analysis of the effect of methylphenidate].[多动症儿童的注意力:哌甲酯效果的信号检测分析]
Z Kinder Jugendpsychiatr. 1987;15(1):6-17.
9
Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity.哌醋甲酯治疗伴有多动的广泛性发育障碍的随机对照交叉试验
Arch Gen Psychiatry. 2005 Nov;62(11):1266-74. doi: 10.1001/archpsyc.62.11.1266.
10
A preliminary study of the relationship between central auditory processing disorder and attention deficit disorder.中枢听觉处理障碍与注意力缺陷障碍关系的初步研究。
J Psychiatry Neurosci. 1993 May;18(3):130-7.

引用本文的文献

1
Sex differences in the response to treatment of attention deficit hyperactivity disorder.注意缺陷多动障碍治疗反应中的性别差异。
Naunyn Schmiedebergs Arch Pharmacol. 2025 Oct 16. doi: 10.1007/s00210-025-04716-5.
2
A Review of Sex and Gender Factors in Stimulant Treatment for ADHD: Knowledge Gaps and Future Directions.多动症兴奋剂治疗中的性别因素综述:知识空白与未来方向
J Atten Disord. 2025 Jun;29(8):602-616. doi: 10.1177/10870547251315601. Epub 2025 Jan 29.
3
Exploring causal associations of antioxidants from supplements and diet with attention deficit/hyperactivity disorder in European populations: a Mendelian randomization analysis.
探索欧洲人群中补充剂和饮食中的抗氧化剂与注意力缺陷多动障碍之间的因果关联:一项孟德尔随机化分析。
Front Nutr. 2024 Sep 24;11:1415793. doi: 10.3389/fnut.2024.1415793. eCollection 2024.
4
Sex Differences in ADHD: Review and Priorities for Future Research.注意缺陷多动障碍的性别差异:综述及未来研究重点。
Curr Psychiatry Rep. 2024 Apr;26(4):151-156. doi: 10.1007/s11920-024-01492-6. Epub 2024 Feb 7.
5
Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).哌醋甲酯治疗注意缺陷多动障碍(ADHD)儿童和青少年。
Cochrane Database Syst Rev. 2023 Mar 27;3(3):CD009885. doi: 10.1002/14651858.CD009885.pub3.
6
Pharmacotherapy for Preschool Children with Attention Deficit Hyperactivity Disorder (ADHD): Current Status and Future Directions.学龄前儿童注意缺陷多动障碍(ADHD)的药物治疗:现状和未来方向。
CNS Drugs. 2021 Apr;35(4):403-424. doi: 10.1007/s40263-021-00806-z. Epub 2021 Mar 26.
7
The female side of pharmacotherapy for ADHD-A systematic literature review.ADHD 药物治疗的女性方面:系统文献综述。
PLoS One. 2020 Sep 18;15(9):e0239257. doi: 10.1371/journal.pone.0239257. eCollection 2020.
8
Does methylphenidate improve academic performance? A systematic review and meta-analysis.哌醋甲酯是否能提高学习成绩?系统评价和荟萃分析。
Eur Child Adolesc Psychiatry. 2019 Feb;28(2):155-164. doi: 10.1007/s00787-018-1106-3. Epub 2018 Jan 20.
9
Premature responding is associated with approach to a food cue in male and female heterogeneous stock rats.在雄性和雌性异质品系大鼠中,过早反应与对食物线索的趋近有关。
Psychopharmacology (Berl). 2016 Jul;233(13):2593-605. doi: 10.1007/s00213-016-4306-x. Epub 2016 May 5.
10
Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).用于治疗儿童和青少年注意力缺陷多动障碍(ADHD)的哌甲酯。
Cochrane Database Syst Rev. 2015 Nov 25;2015(11):CD009885. doi: 10.1002/14651858.CD009885.pub2.